cell isolation News
-
NIH/NCI Small Business Innovation Research Grant, Awarded Fall 2019
Nodexus was selected for an SBIR grant for the development of a novel cancer stem cell detection and isolation platform leveraging the core Nodexus technology ...
By Nodexus Inc.
-
Tissue Genesis, LLC Provides Cell Isolation Processing for Patients with Critical Limb Ischemia (CLI) in Ukrainian Clinical Study
Tissue Genesis, LLC, the leading provider of cell isolation technology is pleased to announce that the Icellator® is being used to generate therapeutic cell preparations at the V.P. Komisarenko Institute of Endocrinology and Metabolism in Kiev, Ukraine, for patients with critical limb ischemia (CLI). The autologous stem-cell therapy, which utilizes a patient’s own fat cells, is the ...
-
Thermo Fisher Scientific Launches First T-Cell Medium Designed Specifically for Allogeneic Cell Therapy Workflows
Thermo Fisher Scientific has developed a new medium for the development and expansion of human T lymphocytes (T-cells) for cell therapy developers using allogeneic workflows. The Gibco CTS OpTmizer Pro Serum Free Media (SFM) is a first-of-its-kind media-solution that targets the metabolism of healthy donor cells, making it ideally suited for use in the production of allogeneic, off-the-shelf cell ...
-
Tissue Genesis LLC, and Human Life CORD Japan, Inc., Announce Exclusive Agreement to Advance Adult Stem Cell Therapies in Asia
Human Life CORD Japan, Inc., (HLC) a group company of Nihon Trim (Cord No. 6788, Tokyo Stock Exchange 1st Section) is pleased to announce a strategic agreement with Tissue Genesis, LLC (TG) to distribute its proprietary stem cell processing products in commercial clinics, research institutions, and hospitals in Japan and China. The 10-year agreement marks a major leap forward in advancing the ...
-
GPB Scientific Announces Initial Availability of Advanced Cell Separation Platform; Name Change to Curate Biosciences
GPB Scientific, Inc. has launched its go-to-market activities for the transformational Curate® Cell Processing System to streamline the manufacture of cell therapies, making them economically and reliably available to the largest number of patients. The company's advanced cell separation platform is in evaluations at select biopharmas, contract manufacturers, and academic centers ahead of the ...
-
RepliCel Terminates License Agreement with Shiseido
RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, announced today that the dispute between Shiseido and RepliCel has led to the Company electing to terminate the license agreement with Shiseido. The Company’s decision is a legal step in its ...
-
New Culture Medium Supports Expansion of Natural Killer Cells for Cell and Gene Therapies
Thermo Fisher Scientific today announced the launch of Gibco Cell Therapy Systems (CTS) NK-Xpander Medium, a GMP-manufactured cell culture medium that supports large-scale growth and culture of functional natural killer (NK) cells with or without the use of feeder cells. This is the first medium from Thermo Fisher specifically designed to support expansion of NK cells for cell therapy ...
-
Replicel Announces Extension to Private Placement
Replicel Life Sciences Inc. (the “Company” or “Replicel”) announces that the TSX Venture Exchange (the “Exchange”) has granted a thirty (30) day extension to the Company for completion of its non-brokered private placement (the “Offering”), previously announced in its News Release of March 21, 2022. The terms of the Private Placement provide for ...
-
Curate Biosciences and City of Hope Evaluate Innovative Cell Separation for HIV CAR-T Cell Therapy Production
Curate Biosciences, a key enabling technology company for cell therapy manufacturing, announced the first outcome of its Technology Access Program, which is dedicated to converting research into real-world treatments and cures as rapidly as possible. City of Hope, one of the largest cancer research and treatment organizations in the United States, has evaluated the Curate® Cell Processing ...
-
Thermo Fisher Scientific and JW Therapeutics Announce CAR-T Partnership in China
Thermo Fisher Scientific, the world leader in serving science, has signed an agreement with JW Therapeutics, a leading cell therapy company, to ensure non-exclusive commercial access to Thermo Fisher's Gibco CTS Dynabeads CD3/CD28. The agreement will support the clinical development and commercial manufacturing of leading CAR-T (Chimeric Antigen Receptor T-Cells) therapies in China, including JW ...
-
RepliCel Closed Final Tranche of Strategic Investment Commitment
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it has closed the final tranche of the investment by MainPointe Pharmaceuticals (“MainPointe”) as outlined in the share purchase agreement signed by the ...
-
Tissue Genesis` Icellator X Delivers Results in First Clinical Application
Tissue Genesis, a leading developer of cell therapy processing systems, announced today that an initial group of patients was successfully treated in the first clinical application of its Icellator® X technology at the Okyanos Center for Regenerative Medicine in Freeport, Bahamas. The new fully enclosed and automated system generated a higher yield of stem cells from adipose (fat) tissue than ...
-
Obesity Primes the Colon for Cancer, According to NIH Study
Obesity, rather than diet, causes changes in the colon that may lead to colorectal cancer, according to a study in mice by the National Institutes of Health. The finding bolsters the recommendation that calorie control and frequent exercise are not only key to a healthy lifestyle, but a strategy to lower the risk for colon cancer, the second leading cause of cancer-related death in the United ...
-
RepliCel Announces Non-brokered Private Placement
RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing novel, next-generation injection technologies as well as regenerative medicine products in aesthetics and orthopedics, is pleased to announce a non-brokered private placement financing (the “Offering”) of up to 8,333,333 units (each, a ...
-
InGeneron Publishes Significant Support for the Existence of Naturally Pluripotent Stem Cells in All Organs in the Adult Body
InGeneron, Inc., a clinical stage regenerative medicine and cell therapy company, announced the publication of the first comprehensive analysis providing significant support for the existence of naturally pluripotent stem cells in all organs. Pluripotent stem cells have the ability to become any cell type of the adult body. The newly-released publication, entitled “Perspective: Why and How ...
-
Thermo Fisher Scientific to Showcase Clinical Research Advances in Immuno-Oncology at AACR
Thermo Fisher Scientific, the world leader in serving science, will present a series of abstracts that will highlight exciting advances in clinical research with applications in immuno-oncology, tumor biology and biomarker discovery during the American Association for Cancer Research (AACR) 2018 Annual Meeting (booth #1805) in Chicago, April 14-18. One abstract presentation (4668) highlights the ...
-
InGeneron Initiates Pivotal Study for its Clinical Lead Program in Rotator Cuff Tendinopathy
InGeneron, Inc., a regenerative medicine and cell therapy company, announced today the enrollment of the first patients in a pivotal study evaluating InGeneron’s cell therapy as a way to treat partial thickness rotator cuff tears involving a partial tear in the supraspinatus tendon. The primary goal of the double-blinded, multi-center trial is to demonstrate the effectiveness of the ...
-
Tissue Genesis Introduces State-of-the-Art Icellator X
Tissue Genesis LLC announced today the release of the Icellator® X, the newest and most advanced system for isolating stem cells in adipose tissue. The Icellator® X expands on the capabilities of the original Icellator®, representing a major advancement in the real-world application of stem therapies for patients. The new-to-market Icellator® X offers greater stem cell ...
-
RepliCel Ships DermaPrecise Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing
RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has shipped DermaPrecise Injector prototypes and consumables to an independent laboratory in Germany to conduct validation studies of injection parameters in various types of ...
-
Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor. ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you